Rankings
▼
Calendar
ACAD FY 2023 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena
ACAD
ACADIA Pharmaceuticals Inc.
$4B
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$726M
+40.4% YoY
Gross Profit
$681M
93.7% margin
Operating Income
-$73M
-10.1% margin
Net Income
-$61M
-8.4% margin
EPS (Diluted)
$-0.37
Cash Flow
Operating Cash Flow
$17M
Free Cash Flow
-$23M
Stock-Based Comp.
$66M
Balance Sheet
Total Assets
$749M
Total Liabilities
$317M
Stockholders' Equity
$432M
Cash & Equivalents
$189M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$726M
$517M
+40.4%
Gross Profit
$681M
$507M
+34.2%
Operating Income
-$73M
-$224M
+67.2%
Net Income
-$61M
-$216M
+71.6%
← Q4 2022
All Quarters
Q1 2023 →